Galena Biopharma (GALE) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Galena Biopharma (GALE) Misses Q2 EPS by 1c

Galena Biopharma Reports Second Quarter 2015 Financial Results

August 6, 2015 4:10 PM EDT

Completed over-enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial and presented encouraging data for GALE-301 and GALE-401 programs Achieved net revenue of $3.4 million for Q2, totaling $6.1 million for 1H, 2015 from Abstral® (fentanyl) Sublingual Tablets; Launched Zuplenz® (ondansetron) Oral Soluble Film in the U.S. on July 29, 2015. Projected full year 2015 net revenue guidance of approximately $15 million Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T.

PORTLAND, Ore., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:... More